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Abstract
High serum uric acid (sUA) has been reported to be a risk factor for hypertension however, whether this is the case for all age groups is
not clear. We examined the association between sUA concentrations and systolic and diastolic blood pressure (SBP and DBP) in
different age groups in a cohort of healthy Chinese participants.
A total of 1082 healthy participants aged from 41 to 70 years were included. sUA concentration was measured by the uricase-
peroxidasemethod. SBP and DBPwere assessed usingmercury sphygmomanometry. Hypertension was deﬁned as SBP≥140mm
Hg or DBP ≥90 mm Hg. Hyperuricemia (HUA) was deﬁned as sUA concentration of>7mg/dL in men and>6mg/dL in women. The
association between sUA concentration and SBP and DBP was examined using Pearson’s correlation test, multivariate linear
regression, and logistic regression analysis.
The prevalence of hypertension and HUA increased with age (P< .001). Hypertension was more common in participants that had
HUA than in those that did not (38.95% vs 30.16%, P= .02). Higher sUA was signiﬁcantly associated with higher SBP and DBP in the
41- to 50-year-old participants (SBP, b=0.35, P< .001; DBP, b= .29, P< .001; after adjustment for age, sex, total cholesterol,
estimated glomerular ﬁltration rate, and fasting plasma glucose). HUA was also a risk factor for hypertension in this age group (odds
ratio 1.425, 95% conﬁdence interval, 1.217–1.668, P< .001). There was no association between sUA concentration and SBP and
DBP in the other age groups.
In this population of healthy Chinese participants, sUA concentration was positively associated with hypertension only in the 41- to
50-year-old group. Lowering uric acid in this age group may help to reduce the incidence of hypertension.
Abbreviations: DBP = diastolic blood pressure, eGFR = estimated glomerular ﬁltration rate, HDL-C = high-density lipoprotein-
cholesterol, HUA = hyperuricemia, LDL-C = low-density lipoprotein-cholesterol, SBP = systolic blood pressure, sCr = serum
creatinine, sUA = serum uric acid, TC = total cholesterol.
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11. Introduction
The prevalence of hypertension is increasing in many countries,
and is an important risk factor for cardiovascular mortality and
morbidity.[1,2] Established risk factors for hypertension include
older age, dyslipidemia, and diabetes.[3] High serum uric acid
(sUA) has been reported to be a risk factor for hypertension in
some cohorts including participants from a healthy Japanese
population.[4–7] In contrast no association between high sUA and
hypertension has been reported in some other cohorts, including
those with established type 1 diabetes.[8,9]
Previous studies suggest that the relation between sUA
concentration and blood pressure may vary at different
ages.[10–14] The National Health and Nutrition Examination
Survey reported that a sUA concentration of >5.5mg/dL was
associated with a 2-fold greater risk of hypertension, and that for
every 0.1mg/dL increase in sUA concentration, the risk of
hypertension was increased by 38% in 12 to 17 years old
people.[10] This relation between sUA concentration and blood
pressure was reported to be absent in a cohort of Chinese
participants aged 90 to 108 years.[11] Similarly, it was reported
that high sUA concentrations were associated with high blood
pressure in Korean participants aged <40 but not ≥40 years
old,[12] whereas this association was only present in Japanese
participants aged ≥40 but not <40 years old.[14] So it is possible
that the relationship between sUA and blood pressure varies at
[13,14]
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between sUA and blood pressure at different ages has not,
however, been previously studied in a Chinese population.
Therefore, in the present study, we aimed to investigate whether
high sUA concentration was associated with hypertension in
different age groups in a Chinese population.2. Methods
2.1. Subjects
A total of 1198 subjects who underwent health examinations
during March to August 2014 were enrolled from the Health
Physical Examination Center of Ganzi Prefecture Hospital,
Sichuan Province, China. Subjects (n=110) with a history of
taking medications which could affect blood pressure or sUA
(including nitrates, corticosteroid, contraceptive pills, antide-
pressant drugs, and antihypertension drugs) were excluded.
Subjects (n=6) with primary liver disease (serum glutamic
pyruvic transaminase >80 IU/L) or primary kidney disease
(estimated glomerular ﬁltration rate [eGFR] <60mL/min/1.73
m2] were also excluded from the study. The remaining 1082
participants were included in the ﬁnal analysis. To investigate
the effect of age on the association between sUA and blood
pressure, subjects were divided into 3 groups according to their
age: 41 to 50 (n=362), 51 to 60 (n=360), and 61 to 70 years
groups (n=360).
The study was approved by the Research Ethics Committees of
Qianfoshan Hospital Afﬁliated to Shandong University, and
Ganzi Autonomous Prefecture Hospital, Sichuan Province. All
participants provided written informed consent.2.2. Baseline measurements and deﬁnitions
Blood pressure was measured in all participants by trained
professionals using conventional mercury sphygmomanometry.
Blood pressure wasmeasured in both arms after the patient rested
for 10 minutes and the higher value was regarded as the blood
pressure of the patient.[15] Blood pressure was measured 3 times
at 2-minute intervals in all participants and mean SBP and DBP
were calculated. Hypertension was deﬁned as SBP ≥140mm Hg,
or DBP ≥90mm Hg.Table 1
Baseline characteristics of the participants.
Variables Total (n=1082) 41–50 y (n=362)
N (male: female) 536:546 181:181
Age, y 55.42±8.60 45.45±2.81
∗
SBP, mm Hg 126.23±20.49 121.33±15.64
DBP, mm Hg 79.40±14.33 76.41±12.46
sUA, mg/dL 5.17±1.80 4.90±1.66
∗
eGFR, mL/min/1.73 m2 99.86±34.81 109.57±4029
∗
TC, mmol/L 4.23±1.13 4.180±1.08
LDL-C, mmol/L 2.78±0.89 2.69±0.81
HDL-C, mmol/L 0.99±0.30 0.99±0.27
Triglyceride, mmol/l 1.13±0.81 1.14±0.96
FPG, mmol/L 4.74±1.52 4.58±1.40
Albumin, g/L 39.30±6.05 40.21±5.62
∗
GOT, IU/L 30.08±23.78 29.56±20.95
Comparison among 3 age groups was performed by a one-way ANOVA.
DBP=diastolic blood pressure, eGFR= estimated glomerular ﬁltration rate, GOT=glutamic-oxaloacetic tra
N=number, PFG= fasting plasma glucose, SBP= systolic blood pressure, sUA= serum uric acid, TC=
∗
P< .05, compared with both of the other 2 age groups by post hoc Duncan test.
2Venous blood samples were collected after an overnight fast
(≥12hours). sUA concentrations were measured by the uricase-
peroxidase method.[16] According to the Chinese Expert
Consensus on hyperuricemia (HUA) and gout treatment, HUA
was deﬁned as sUA concentration of >7mg/dL in men and >6
mg/dL inwomen.[17] The following additional serum biochemical
parameters were measured using the Olympus AU2700 auto-
matic biochemical analyzer: glutamic-oxaloacetic transaminase,
albumin, total cholesterol (TC), triglyceride, low-density lipo-
protein-cholesterol (LDL-C), high-density lipoprotein-cholester-
ol (HDL-C), serum creatinine (sCr), and fasting plasma glucose.
eGFR was calculated using the Modiﬁcation of Diet in Renal
Disease (MDRD) equation: eGFR=186.3 (sCr in mg/dL)1.154
age0.2030.827 (for Chinese)1 (for men) or 0.742 (for
women).[18,19]2.3. Statistical analysis
The data were normally distributed according to the Kolmo-
gorov–Smirnov normality test. All statistical analyses were
performed using SPSS version 19.0. Continuous data were
presented as mean± standard deviation. Comparison among
means was performed by a one-way ANOVA followed by
Duncan test post hoc test. The x2 test was used to compare the
prevalence of hypertension or HUA among different age groups.
Correlation was assessed by Pearson’s test. Multiple linear
regression analysis was used to analyze the contribution of age,
sex, TC, eGFR, and fasting plasma glucose to the association of
sUA concentration with SBP and DBP, and logistic regression
analysis was used to analyze the contribution of these factors to
the association of HUA with hypertension. A P value of <0.05
was regarded as statistically signiﬁcant.3. Results
The baseline characteristics of the 1082 participants were
summarized in Table 1. The participants were divided into 3
groups aged 41 to 50 (n=362), 51 to 60 (n=360), and 61 to 70
(n=360) years. The sex ratio, HDL, triglyceride, and glutamic-
oxaloacetic transaminase were comparable among these 3 groups
(P> .05). There was a signiﬁcant difference among the groups in
the following parameters: SBP, DBP, sUA, eGFR, total51–60 y (n=360) 61–70 y (n=360) P
178:182 177:183 >.05
55.54±2.83
∗
65.32±2.90
∗
<.001
123.38±18.49 134.30±24.14
∗
<.001
78.31±13.80 83.51±15.63
∗
<.001
5.26±1.78 5.34±1.93 <.001
97.63±34.59
∗
92.32±25.73
∗
<.05
4.20±1.19 4.42±1.10
∗
<.01
2.74±0.98 2.90±0.86
∗
<.01
0.99±0.32 1.01±0.32 >.05
1.11±075 1.14±0.69 >.05
4.77±1.30 4.88±1.81 <.05
39.27±6.29 38.48±6.12 <.001
31.09±26.52 29.60±23.58 >.05
nsaminase, HDL-C=high-density lipoprotein-cholesterol, LDL-C= low-density lipoprotein-cholesterol,
total cholesterol.
Table 2
The prevalence of HUA and hypertension in different age groups.
Variables Total (n=1082) 41–50 y (n=362) 51–60 y (n=360) 61–70 y (n=360) P
Hypertension 345 (31.88%) 73 (20.17%)
∗
107 (29.72%)
∗
165 (45.83%)
∗
<.001
HUA 190 (17.56%) 52 (14.36%) 56 (15.56%) 82 (22.78%)
∗
.006
Comparison among 3 age groups was performed by a one-way ANOVA.
HUA=hyperuricemia.
∗
P< .05, compared with both of the other 2 age groups by post hoc Duncan’s test.
Table 3
Multivariate linear regression analysis of the association between
blood pressure and uric acid.
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min (Table 1). The difference in eGFR between any 2 age groups
was signiﬁcant (P< .05). SBP, DBP, total cholesterol, LDL-
cholesterol of the 61 to 70 years age group were signiﬁcantly
higher than those of the 41 to 50 and 51 to 60 years age groups
(P< .05). sUA levels of both the 51 to 60 and 61 to 70 years age
groups were signiﬁcantly higher than that of the 41 to 50 years
age group (P< .05). The fasting plasma glucose level of the 61 to
70 years age group was higher than that of the 41 to 50 years age
group (P< .05) (Table 1).
The prevalence of hypertension increased with age. The
prevalence of hypertension in the 61 to 70 years age group
(45.83%) was signiﬁcantly higher than that in both the 41 to 50
years age group (20.17%, P< .001) and the 51 to 60 years age
group (29.72%, P< .001; Table 2). The prevalence of hyperten-
sion in the 51 to 60 years age group (29.72%) was also
signiﬁcantly higher than that in the 41 to 50 years age group
(20.17%, P< .05; Table 2).
A similar trendwas observed forHUA. The prevalence of HUA
in the 61 to 70 years age group (22.78%) was signiﬁcantly higher
than that in both the 41 to 50 years age group (14.36%, P= .006)
and the 51 to 60 years age group (15.56%, P= .006).
The prevalence of hypertension in participants with HUA was
signiﬁcantly higher than that of participants with normal uric
acid levels (38.95% vs 30.16%, P< .05; Fig. 1).
According to the multivariate linear regression analysis, higher
sUA was signiﬁcantly associated with higher SBP in the whole
cohort (b = 0.10, P=0.001; Table 3). Further analysis suggested
that sUA concentration was signiﬁcantly positively associated
with both SBP and DBP in the 41 to 50 years age group (SBP, b =
0.35, P<0.001; DBP, b = 0.29, P< .001; Table 3) afterFigure 1. The prevalence of hypertension in participants that had hyperur-
icemia and those with normal uric acid levels.
∗
P< .05.
3adjustment for age, sex, TC, eGFR, and fasting plasma glucose
but not in other age groups.
Multiple logistic regression analyses suggested that HUA was
not signiﬁcantly associated with hypertension (odds ratio 1.073,
95% conﬁdence interval [CI], 0.989–1.164, P= .088; Table 4) in
the whole cohort. However, HUA was signiﬁcantly associated
with hypertension in the 41 to 50 years age group (odds ratio
1.425, 95% CI, 1.217–1.668, P< .001; Table 4).4. Discussion
The present study suggested that the relationship between HUA
and hypertension is limited to younger participants in a healthy
Chinese population with normal blood pressure, sUA, kidney
function, and lipid proﬁle. We found this association to be
present in participants aged 41 to 50 years but not 51 to 70 years.
A number of epidemiological studies have reported that HUA is
accompanied with hypertension.[20,21] The positive correlation
betweenelevatedsUAandhypertensionhasbeendescribed inmany
populations,[10,22–25] and increasing amounts of evidence suggests
that sUA is a causal contributor to hypertension.[4,26,27] In a large
cohort study involving 2062 participants with amean follow-up of
21.5 years it was reported that high sUA concentration was
independently associated with the incidence of developing
hypertension (RR: 1.05, 95% CI, 1.01–1.10, P= .02).[4]
Renal insufﬁciency[28] and liver disease[29] are associated with
HUA, and they are also well-established mechanisms for
secondary hypertension. We, however, excluded patients withSBP DBP
ß R2 P ß R2 P
Total 0.10 0.14 .001 0.04 0.11 .22
41–50 y 0.35 0.12 <.001 0.29 0.08 <.001
51–60 y 0.05 0.10 .38 0.03 0.15 .57
61–70 y 0.07 0.08 .20 0.03 0.05 .59
Age, sex, total cholesterol, glomerular ﬁltration rate, and fasting plasma glucose were adjusted for.
DBP=diastolic blood pressure, SBP= systolic blood pressure.
Table 4
Multivariate logistic regression analysis of the association
between hyperuricemia and hypertension in different age groups.
Groups OR CI P
Total 1.073 0.989–1.164 .088
41–50 y 1.425 1.217–1.668 <.001
51–60 y 0.959 0.822–1.119 .599
61–70 y 1.056 0.941–1.185 .355
Age, sex, total cholesterol, glomerular ﬁltration rate, and fasting plasma glucose were adjusted for.
CI=conﬁdence interval, OR= odds ratio.
2 [3] Saraﬁdis PA, Bakris GL. State of hypertension management in the United
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(serum glutamic pyruvic transaminase > 80IU/L). Therefore, the
association between HUA and hypertension in the present study
is not due to renal insufﬁciency or liver disease.
Our study suggested that with aging, the incidence of
hypertension in the 61 to 70 years age group was 2.27 times
higher than that in the61 to70years agegroup.Only in the41 to50
years age group, there was a signiﬁcant correlation between sUA
and blood pressure. Our observation that age affected the
correlation between sUA and blood pressure is consistent with
some previous reports.[12] A signiﬁcant association between sUA
and blood pressure was reported in Korean adults aged<60 years
but not those aged>60years for example.[12]The exactmechanism
for the age-related relationship between sUA and blood pressure is
still unknown. Whether the age relationship between sUA and
blood pressure is due to the difference in ethnicity, certain single-
nucleotide polymorphisms, body mass index,[30] or oxidative
oxygen species[31] needs to be further studied.
It has been reported that sUA is a consistent cardiovascular risk
factor in different populations[32–35] and suggested that lowering
sUA with allopurinol may reduce cardiovascular events.[36,37] It
is likely that sUA promotes cardiovascular risk but multiple
mechanisms including those unrelated to hypertension such as
causing endothelia dysfunction,[38] increasing oxidative stress,[39]
and inducing renal arteriolopathy.[40,41] As a result monitoring
and lowering sUA levels may be helpful in decreasing
cardiovascular events in all age groups, although this remains
to be deﬁnitely demonstrated.
This study has several limitations. First, its cross-sectional
design precludes any causal relationships between UA and
hypertension being assumed. Second, the blood pressure in the
participants was relatively low and therefore the results should
not be extrapolated to populations with higher blood pressure.
Third, the participants were all Chinese and whether the ﬁndings
are similar in other ethnicities needs to be further investigated.
Fourth, we adjusted for a variety of important confounding
variables of hypertension including age, sex, TC, eGFR, and
fasting plasma glucose. However, we did not have information
about smoking or physical activity which may affect blood
pressure. Residual confounding likely remains.5. Conclusions
Our data suggest that age affects the correlation between sUA and
bloodpressure. sUAwaspositively associatedwithbloodpressure in
the 41 to 50 years age group, but not in older participants. Lowering
sUA in younger Chinese adults may be helpful in reducing the
incidence of hypertension although this remains to be proven.Acknowledgments
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